FY2025 Earnings Forecast for Vericel Issued By HC Wainwright

Vericel Co. (NASDAQ:VCEL - Free Report) - Equities researchers at HC Wainwright decreased their FY2025 EPS estimates for Vericel in a research report issued to clients and investors on Friday, February 28th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.26 for the year, down from their prior estimate of $0.35. HC Wainwright currently has a "Buy" rating and a $60.00 target price on the stock. The consensus estimate for Vericel's current full-year earnings is $0.14 per share. HC Wainwright also issued estimates for Vericel's FY2027 earnings at $1.18 EPS, FY2028 earnings at $1.93 EPS and FY2029 earnings at $2.66 EPS.

VCEL has been the subject of several other research reports. Stephens reissued an "overweight" rating and set a $65.00 price objective on shares of Vericel in a report on Wednesday, January 15th. BTIG Research boosted their price target on shares of Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Truist Financial restated a "buy" rating and set a $61.00 price objective (down previously from $67.00) on shares of Vericel in a research report on Monday. StockNews.com downgraded shares of Vericel from a "hold" rating to a "sell" rating in a report on Friday, February 28th. Finally, Canaccord Genuity Group increased their target price on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Vericel currently has a consensus rating of "Moderate Buy" and an average target price of $62.29.

Remove Ads

Vericel Stock Performance

Vericel stock traded down $2.77 during midday trading on Monday, hitting $48.76. 315,355 shares of the company's stock were exchanged, compared to its average volume of 418,659. The company has a market cap of $2.41 billion, a P/E ratio of 812.80 and a beta of 1.72. The stock has a 50-day moving average price of $56.63 and a two-hundred day moving average price of $51.91. Vericel has a 52-week low of $39.12 and a 52-week high of $63.00.

Insider Buying and Selling

In other news, insider Jonathan Siegal sold 3,908 shares of the firm's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total transaction of $242,256.92. Following the transaction, the insider now directly owns 1,206 shares of the company's stock, valued at approximately $74,759.94. This trade represents a 76.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the sale, the director now directly owns 26,595 shares of the company's stock, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,500 shares of company stock worth $466,200 in the last 90 days. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vericel

A number of large investors have recently added to or reduced their stakes in VCEL. International Assets Investment Management LLC grew its position in shares of Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock worth $27,000 after buying an additional 619 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new stake in Vericel in the fourth quarter worth $48,000. GF Fund Management CO. LTD. bought a new stake in Vericel in the fourth quarter valued at $57,000. Farther Finance Advisors LLC increased its position in Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 405 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in Vericel by 511.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock worth $70,000 after purchasing an additional 1,058 shares in the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.